Hansa Medical interim report January – September 2015 (Hansa Medical AB)

(Source: Hansa Medical AB) January - September 2015 in summary Significant events during the third quarter Hansa Medical received FDA Orphan Drug Designation for IdeS in solid organ transplant patientsFirst patient treated and transplanted with IdeS in US Phase II study at Cedars-Sinai Medical Center, Los AngelesPositive IdeS Phase I data published in scientific journal PLOS ONEData from Hansa Medical's first Phase II study of IdeS in Sensitized Kidney Transplantation Patients presented at an oral session at ESOT 2015Results from a clinical multicenter trial with HBP-assay published in Critical Care Medicine Financial Summary Third Quarter and Year to Date Net sales for the group in Q3...